| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools. 
|
|
Today’s Big NewsFeb 13, 2025 |
| By James Waldron A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, the asset has failed its phase 3 trial. |
|
|
|
By Nick Paul Taylor Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. |
By Gabrielle Masson Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments, plus several clinical programs from Roche in hand. |
By James Waldron Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage R&D to focus resources on its Dravet syndrome program. |
|
Join us for an expert discussion on how to navigate complex DSCSA requirements in this rapidly advancing field. Explore the systems, processes and technologies that are crucial to safeguard patients. 
|
|
By James Waldron Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ended work to recalibrate the business. |
By James Waldron Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations. |
By Darren Incorvaia After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts. |
By Darren Incorvaia Less than a month after researchers unveiled that a “ticking DNA clock” is behind Huntington’s disease, scientists have now identified an antisense oligonucleotide that can slow down the disease-causing gene expansion process. |
By Darren Incorvaia Michigan-based clinical research organization MMS is boosting its data science power with a new purchase from the U.K. The firm has acquired the Northern Irish data science company Exploristics, gaining access to its cloud-based statistical modeling and simulation platform. |
By Angus Liu Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug's already broadest-in-class U.S. label in prostate cancer. |
By Heather Landi Hims & Hers hit the bullseye with its Super Bowl ad—it sparked a lot of attention from consumers for its brand and weight loss products. But the controversial ad also caught the attention of the pharma industry and lawmakers, who lashed the company for "deceptive" advertising. |
By Noah Tong Pressure is picking up on congressional Republicans to agree on spending cuts, and all eyes are on how leadership intends to remake Medicaid. |
Fierce podcasts Don’t miss an episode |
| A recent report, released at this year’s J.P. Morgan Healthcare Conference, lays out the high-growth potential of the women’s health market and its promised return on investment. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
